The UK Patents Court has referred four questions to the Court of Justice of the European Union (CJEU) seeking clarification on how the Supplementary Protection Certificate (SPC) Regulation should be interpreted in relation to drug products made of a combination of active ingredients.
If you have already subscribed please login.
If you have any technical issues please email tech support.
SPC, CJEU, Actavis, Boehringer Ingelheim, MicardisPlus
